Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CTLA-4
Pharma
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
If approved by the FDA, BMS' Opdivo-Yervoy combo will go toe to toe with Roche's and AstraZeneca's immunotherapies in first-line liver cancer.
Angus Liu
Mar 20, 2024 10:18am
BMS shows I-O duo's power in first-line colorectal cancer
Jan 20, 2024 10:00am
BMS, AZ settle cancer immunotherapy patent suits for $510M
Aug 1, 2023 10:09am
AstraZeneca's CTLA-4 drug treme finally snags its first approval
Oct 24, 2022 10:48am